How do we treat cutaneous T-cell lymphoma?

Area of Science:

• Oncology
• Dermatology
• Hematology

Background:

• Cutaneous T-cell lymphomas (CTCL) represent a diverse group of non-Hodgkin lymphomas characterized by malignant T lymphocytes in the skin.
• Subtypes of CTCL exhibit significant variability in clinical presentation, disease course, and treatment response.
• While allogeneic stem cell transplantation offers a curative potential, its associated risks necessitate careful consideration.

Purpose of the Study:

• To review current treatment strategies for cutaneous T-cell lymphomas.
• To emphasize the development of therapeutic concepts that manage the indolent, chronic nature of CTCL.
• To balance effective disease control with minimized side effects and preserved quality of life.

Main Methods:

• Review of current guidelines and relevant literature on CTCL treatment.
• Integration of clinical experience in managing CTCL subtypes.
• Discussion of a phased therapeutic approach, starting with skin-oriented therapies and progressing to systemic agents.

Main Results:

• CTCL treatment requires a tailored approach due to subtype heterogeneity.
• Early-stage management typically involves skin-directed therapies.
• Advanced disease necessitates systemic treatments, with stem cell transplantation as a curative but high-risk option.

Conclusions:

• A comprehensive therapeutic strategy for CTCL should prioritize quality of life and minimize adverse effects.
• Treatment escalation should be guided by disease progression and subtype.
• This review provides a framework for managing CTCL based on current evidence and clinical practice.